Johnson & Johnson

06/14/2024 | Press release | Distributed by Public on 06/14/2024 14:30

Findings from landmark RESONATE 2 study confirm sustained survival benefit of IMBRUVICA® (ibrutinib) for first line chronic lymphocytic leukaemia treatment with up to 10 years[...]